Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
about
Metastatic disease from uveal melanoma: treatment options and future prospectsPathways and therapeutic targets in melanomaARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal MelanomaMelanoma epidemiology, biology and prognosis.Understanding the biology of melanoma and therapeutic implicationsMelanoma: clinical features and genomic insights.The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.Back to the future: oral targeted therapy for RA and other autoimmune diseases.Biology of advanced uveal melanoma and next steps for clinical therapeutics.Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers.Doubling down on PKC benefits allogeneic BMT.The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.Intracellular Ca2+ oscillations generated via the Ca2+-sensing receptor are mediated by negative feedback by PKCα at Thr888Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.The biology of uveal melanomaMelanoma mutagenesis and aberrant cell signaling.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects.Simulated annealing molecular dynamics and ligand-receptor contacts analysis for pharmacophore modeling.RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.Protective role and related mechanism of Gnaq in neural cells damaged by oxidative stress.Novel mouse model for primary uveal melanoma: a pilot study.The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.INPP4B suppresses prostate cancer cell invasionIntegrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.Identifying the Biphasic Role of Calcineurin/NFAT Signaling Enables Replacement of Sox2 in Somatic Cell Reprogramming.Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.PKCα promotes local advancement via its dual roles in nasopharyngeal carcinoma.Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.
P2860
Q26738377-61EB9C3E-D134-4277-A468-B28277D0C7CAQ26865736-9598F1B9-5250-4DAB-9D12-B3739A0B4430Q28115305-4D91E44C-F2A3-4143-BC6E-79318F62D5E6Q33698718-44633021-5965-4AE7-99ED-09F0152E2529Q33978378-31159AF7-3B51-416F-90CE-B638B77BFEF3Q34083191-6D9BAFBA-E1F2-4CFB-B0B8-3F81F670D45EQ34096861-7C9A45C9-6C99-4A90-AF38-0422CE5C62BCQ34213332-73ACCB37-DD81-4B23-B251-89ED5E6831E4Q35079709-E4B0CC15-878D-4AF7-AD8F-F4A329CCF25BQ35915107-0F0D8959-37D5-4F7D-81F0-C3B50DC2D453Q36244879-92DEBF0D-93FF-4AFA-AECC-7E8A8ABD95C2Q37215114-2EB7057E-F7F0-48FD-9144-EF770D76CEFDQ37269087-4F4CD7E6-D1C2-4C91-8E1F-A0CD3CED94CCQ37575337-28ED1C64-B660-44AB-949D-C9E445A41F70Q37691937-66CDF26B-2269-4F6F-971E-4C8F00EB32A0Q37742632-4EC2517B-E104-4A64-AEFB-3E7AC66CBA53Q38146707-AB39128D-CFA2-4A77-9D41-E427057BCB66Q38221107-A9F12BD6-DA47-4CD5-B460-EE4B3492077EQ38297995-2F8AED00-267E-4F6F-99DD-ABDED2141C3CQ38655350-F4B099E7-119A-4528-B49A-E0464A82A2DEQ38704201-F6973946-DCD5-4446-8680-9A08477C12D2Q38709250-B8E040A6-BE7A-4EE8-88E5-15B1BAB7A051Q38752881-3B9988A8-06B6-4F00-8209-15383276393AQ38909389-2411CE39-4A12-4C3E-9825-0C6878347E56Q38953956-30D1D1D4-7FBE-4790-95E2-83512C5DD6A7Q40082486-2CA289E5-2D59-4232-8F7C-804238647480Q40367768-05887299-C4A6-40B7-AED1-37074EFF5C8AQ41609825-3BF1714C-0EC1-40E9-B32E-2E90F183C5BAQ50102285-40D19A96-48FA-4C0C-9FF9-7E8ED8EC5327Q52640287-E6F424E7-3559-44DE-93DC-6C68EBA79720Q52801310-F1C6C71E-1171-4CD3-BF33-3BF40C20CCC5Q54118869-BF05AFDF-F93C-4C56-82C7-038E3AA15628Q54154496-D993A305-C7FE-41A0-B597-2772C842A5A2Q55352057-766D5C05-25B9-4F7E-BE0E-115CAA842998
P2860
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Protein kinase C inhibitor AEB ...... Erk1/2 and PKC/NF-κB pathways.
@en
type
label
Protein kinase C inhibitor AEB ...... Erk1/2 and PKC/NF-κB pathways.
@en
prefLabel
Protein kinase C inhibitor AEB ...... Erk1/2 and PKC/NF-κB pathways.
@en
P2093
P2860
P1476
Protein kinase C inhibitor AEB ...... Erk1/2 and PKC/NF-κB pathways.
@en
P2093
F Stephen Hodi
Jingjing Li
Jonathan A Fletcher
Meijun Zhu
P2860
P304
P356
10.1158/1535-7163.MCT-12-0121
P577
2012-05-31T00:00:00Z